Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach

Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.